Kosan Biosciences Incorporated

Other

Bristol-myers Squibb Compnay

Koasn Biosciences Incorporated

Peter J Licari

John R Carney

Alexander Redvers Eberlin

Jorge L Galazzo

Greg O Buchanan

Chaitan Khosla

Mark D Eddleston

Ruchir Desai

Timothy Leaf

Bryan Julien

Ziyang Zhong

Indu Isaacs

Robert L Arslanian

John G Augustine

Stephen William Watt

Lawrence Cadapan

Hiroko Tsuruta

Scott Frykman

Elaine Jennifer Woo

Robert Arslanian

Greg Buchanan

Alexander Redvers Erberlin

Mark Eddleston

Formulations of desoxyepothilones are stable before and after dilution into aqueous media.

Therapeutic formulations of desoxyepothilones

The invention provides polymorphs of a motilide having a structure represented by formula Ia 

Motilide polymorphs

Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxygeldanamycin (17-AAG).

17-allylamino-17-demethoxygeldanamycin polymorphs and formulations

During the production of a product compound by fermentation, the concentration of a precursor compound is maintained within a pre-selected concentration range by having an adsorbent resin in contact with the culture medium. The adsorbent resin reversibly adsorbs precursor compound and, as un-adsorbed precursor compound is converted to product compound, adsorbed precursor compound is released from the resin, thus maintaining the concentration of precursor compound within the pre-selected range.

Method of producing a compound by fermentation

Migrastatin and a migrastatin analog can be produced by fermentation ofNRRL 18993 and used in pharmaceutical formulations to treat cancer and/or inhibit metastasis of cancer cells.

Fermentation and purification of migrastatin and analog

The present invention provides a generalized oxygen-limited cultivation method for myxobacterial strains engineered to heterologously express polyketides synthase (PKS) gene clusters under various oxygen tension conditions, modulating the polyketide congener distribution.

Secondary metabolite congener distribution modulation

Migrastatin and a migrastatin analog can be produced by fermentation of NRRL 18993 and used in pharmaceutical formulations to treat cancer and/or inhibit metastasis of cancer cells.

Fermentation based methods for producing mycolactones allows one to produce large quantities of mycolactones, which can be purified by extraction and chromatography to yield pure preparations of mycolactones A, B, C, and D.

Fermentation and purification of mycolactones

Growing community of inventors

Fremont, CA, United States of America

Peter J Licari